biostudies-literatureUnknownLlor CInstituto de Salud Carlos IIIMinistry of Science and InnovationSpanish Clinical Research NetworkGovernment of SpainEuropean Regional Development Fund<h4>Background</h4>Despite the frequent use of symptomatic therapies in cough, evidence of their benefits is lacking.<h4>Objective</h4>We compared the effectiveness of 3 symptomatic therapies and usual care in acute bronchitis.<h4>Methods</h4>Multicenter, pragmatic, multiarm parallel group, open randomized trial in primary care (ClinicalTrials.gov, Identifier: NCT03738917) was conducted in Catalonia. Patients ≥18 with uncomplicated acute bronchitis, with cough<3 weeks as the main symptom, scoring ≥4 in either daytime or nocturnal cough (7-point Likert scale), were randomized to usual care, dextromethorphan 15 mg t.i.d., ipratropium bromide inhaler 20 µg 2 puffs t.i.d, or 30 mg of honey t.i.d., all taken for up to 14 days. The main outcome measure was the number of days with moderate-to-severe cough. A symptom diary was given. A second visit was scheduled at days 2-3 for assessing evolution, with 2 more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance, and complications.<h4>Results</h4>We failed to achieve the sample size scheduled due to the COVID-19 pandemic. We finally recruited 194 patients. The median number of days with moderate-to-severe cough (score ≥ 3) in the usual care arm was 5 (interquartile range [IQR], 4, 8.75), 5 in the ipratropium bromide arm (IQR, 3, 8), 5 in the dextromethorphan arm (IQR, 4, 9.75), and 6 in the honey arm (IQR, 3.5, 7). The same results were obtained in the Kaplan-Meier survival analysis for the median survival time of each arm with the usual care as the reference group.<h4>Conclusion</h4>The symptomatic treatment evaluated has shown to be ineffective against cough.Family practicecmac112https://www.ebi.ac.uk/biostudies/studies/S-EPMC9619792biostudies-literatureEffectiveness of antitussives, anticholinergics, and honey versus usual care in adults with uncomplicated acute bronchitis: a multiarm randomized clinical trial.PMC9619792PI17/01345PT17/0017/0005Llor CGarcia-Sangenis AMoragas APera HOuchi DGomez-Lumbreras AMorros RMonfa RPujol JfalseEffectiveness of antitussives, anticholinergics, and honey versus usual care in adults with uncomplicated acute bronchitis: a multiarm randomized clinical trial.<h4>Background</h4>Despite the frequent use of symptomatic therapies in cough, evidence of their benefits is lacking.<h4>Objective</h4>We compared the effectiveness of 3 symptomatic therapies and usual care in acute bronchitis.<h4>Methods</h4>Multicenter, pragmatic, multiarm parallel group, open randomized trial in primary care (ClinicalTrials.gov, Identifier: NCT03738917) was conducted in Catalonia. Patients ≥18 with uncomplicated acute bronchitis, with cough<3 weeks as the main symptom, scoring ≥4 in either daytime or nocturnal cough (7-point Likert scale), were randomized to usual care, dextromethorphan 15 mg t.i.d., ipratropium bromide inhaler 20 µg 2 puffs t.i.d, or 30 mg of honey t.i.d., all taken for up to 14 days. The main outcome measure was the number of days with moderate-to-severe cough. A symptom diary was given. A second visit was scheduled at days 2-3 for assessing evolution, with 2 more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance, and complications.<h4>Results</h4>We failed to achieve the sample size scheduled due to the COVID-19 pandemic. We finally recruited 194 patients. The median number of days with moderate-to-severe cough (score ≥ 3) in the usual care arm was 5 (interquartile range [IQR], 4, 8.75), 5 in the ipratropium bromide arm (IQR, 3, 8), 5 in the dextromethorphan arm (IQR, 4, 9.75), and 6 in the honey arm (IQR, 3.5, 7). The same results were obtained in the Kaplan-Meier survival analysis for the median survival time of each arm with the usual care as the reference group.<h4>Conclusion</h4>The symptomatic treatment evaluated has shown to be ineffective against cough.2022-01-01T00:00:00Z2022 Oct2024-11-08T16:06:06.85Z2024-11-08T16:06:06.85ZS-EPMC96197923623919910.1093/fampra/cmac112